Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Treasury Shares (2022 - 2026)

bioAffinity Technologies has reported Treasury Shares over the past 5 years, most recently at $51810.0 for Q1 2026.

  • Quarterly Treasury Shares fell 96.7% to $51810.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $51810.0 through Mar 2026, down 96.7% year-over-year, with the annual reading at $51810.0 for FY2025, 17.06% up from the prior year.
  • Treasury Shares was $51810.0 for Q1 2026 at bioAffinity Technologies, roughly flat from $51810.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $1.6 million in Q1 2025 and troughed at $44261.0 in Q4 2024.
  • The 5-year median for Treasury Shares is $540969.0 (2023), against an average of $641512.2.
  • Year-over-year, Treasury Shares surged 370.74% in 2023 and then crashed 96.7% in 2026.
  • A 5-year view of Treasury Shares shows it stood at $114920.0 in 2022, then skyrocketed by 370.74% to $540969.0 in 2023, then crashed by 91.82% to $44261.0 in 2024, then grew by 17.06% to $51810.0 in 2025, then changed by 0.0% to $51810.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Treasury Shares are $51810.0 (Q1 2026), $51810.0 (Q4 2025), and $51849.0 (Q3 2025).